Somite Therapeutics Achieves Key Milestone with FDA Orphan Drug and Rare Pediatric Disease Designations for SMT-M01 in Duchenne Muscular Dystrophy
Somite Therapeutics has announced a major breakthrough in the fight against Duchenne Muscular Dystrophy (DMD), securing both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the FDA for their lead therapeutic candidate, SMT-M01. These designations are critical in the development of therapies targeting rare diseases, offering benefits such as tax credits for […]
How Somite Therapeutics and OmniaBio Are Revolutionizing Cell Therapy for Duchenne Muscular Dystrophy
In an exciting new collaboration, Somite Therapeutics and OmniaBio Inc. have joined forces to advance Somite’s flagship cell therapy program, targeting the devastating genetic disorder Duchenne Muscular Dystrophy (DMD). This strategic partnership leverages Somite’s cutting-edge use of AI-driven cell replacement therapies and OmniaBio’s expertise in induced pluripotent stem cells (iPSCs) to bring hope to individuals […]
$500,000 Awarded for Groundbreaking Duchenne Muscular Dystrophy Trial
In a landmark announcement, Duchenne UK and Parent Project Muscular Dystrophy (PPMD) have committed $500,000 to a pioneering Phase 1 clinical trial aimed at evaluating the safety and tolerability of muscle progenitor cells in patients with Duchenne Muscular Dystrophy (DMD). This trial represents a significant advancement in the quest to find effective treatments for this […]